Gleamer announced a Series B financing of €27 million (~USD $30 million). This new investment will enable Gleamer to expand its portfolio of solutions, strengthen its European and American teams and accelerate international development plans. Total funds raised to date amount to €36 million (which includes a Series A funding round of €7.5 million in 2020 and seed funding of €1.5 million in 2018).
Gleamer has developed a comprehensive suite of artificial intelligence (AI)-powered solutions for standard radiography including BoneView for detecting bone trauma lesions, BoneMeasurement for automating musculoskeletal measurements, and BoneAge for automating bone age estimation. All three solutions hold MDR class IIa CE certification in Europe. BoneView has also received FDA clearance for use in adults and children over the age of two, making it the first and only AI-powered solution certified for detecting bone fractures in adults and children in the United States.
The company aims to accelerate its international expansion, particularly in Europe and in the United States where the sales teams will be strengthened. Gleamer will extend existing strategic partnerships, while signing new large-scale partnerships to make Gleamer’s solutions accessible to as many people as possible.
“This new round of funding will allow us to deepen Gleamer’s mission of making AI the new standard of care in radiology. Our aim is to increase diagnostic accuracy and improve patient care and the efficiency of clinical practices for health professionals,” said Christian Allouche, CEO and co-founder of Gleamer.
Gleamer announced a Series B financing of €27 million (~USD $30 million). This new investment will enable Gleamer to expand its portfolio of solutions, strengthen its European and American teams and accelerate international development plans. Total funds raised to date amount to €36 million (which includes a Series A funding round of €7.5 million...
Gleamer announced a Series B financing of €27 million (~USD $30 million). This new investment will enable Gleamer to expand its portfolio of solutions, strengthen its European and American teams and accelerate international development plans. Total funds raised to date amount to €36 million (which includes a Series A funding round of €7.5 million in 2020 and seed funding of €1.5 million in 2018).
Gleamer has developed a comprehensive suite of artificial intelligence (AI)-powered solutions for standard radiography including BoneView for detecting bone trauma lesions, BoneMeasurement for automating musculoskeletal measurements, and BoneAge for automating bone age estimation. All three solutions hold MDR class IIa CE certification in Europe. BoneView has also received FDA clearance for use in adults and children over the age of two, making it the first and only AI-powered solution certified for detecting bone fractures in adults and children in the United States.
The company aims to accelerate its international expansion, particularly in Europe and in the United States where the sales teams will be strengthened. Gleamer will extend existing strategic partnerships, while signing new large-scale partnerships to make Gleamer’s solutions accessible to as many people as possible.
“This new round of funding will allow us to deepen Gleamer’s mission of making AI the new standard of care in radiology. Our aim is to increase diagnostic accuracy and improve patient care and the efficiency of clinical practices for health professionals,” said Christian Allouche, CEO and co-founder of Gleamer.
Copy to clipboard 
